European award for medicinal chemists: New active ingredients for the treatment of infections

Martin Empting works towards the development of new active substances that can be used to treat bacterial and viral infections. He has now been awarded the Young Medicinal Chemist in Academia Prize by the European Federation of Medicinal Chemistry (EFMC) as a runner-up. This prize is aimed at young chemists who are pursuing a career in academic research.

Background Research:
Martin Empting is a significant figure in the arena of medicinal chemistry. He is intensely focused on creating new active ingredients, which could be instrumental in managing bacterial and viral infections. The European Federation for Medicinal Chemistry (EFMC) has recognized his efforts and rewarded him with the Young Medicinal Chemist in Academia Prize as runner-up.

Medicinal Chemistry is a specialized area of study within the domain of chemistry. It significantly deals with the development, discovery, and design of new pharmaceutical drugs. Generally, practitioners apply their chemistry expertise to discover and develop new therapeutics.

The European Federation for Medicical Chemistry (EFMC) is an independent body representing medicinal chemistry societies from Europe and Israel. Their goal includes promoting advancements in medical research and recognising young talents through awards like The Young Medicinal Chemist in Academia Prize.

FAQs:

1. Who is Martin Empting?
– Martin Empting is a medicinal chemist who specializes in developing new active substances to treat bacterial and viral infections.

2. What did Martin Empting receive?
– He received the Young Medicinal Chemist in Academia Prize from the European Federation for Medical Chemistry (EFMC).

3.Why was he awarded this prize?
– Martin was awarded this prize because of his commitment to developing new therapeutic agents that can assist significantly against bacterial or viral infections.

4.What does ‚Young Medicinal Chemist In Academia‘ Award signify?
– The award acknowledges young chemists making strong advancements into academic research oriented towards medicinal chemistry specializations.

5.What do we mean by „active substances“ against bacteria or viruses?
– „Active substances“ refers to components that are effective against diseases- they can kill bacteria/viruses or hinder their replication thereby treating infection effectively.

6.How do these awards impact scientists like Martin Empting?
– These awards provide recognition on an international scale and often open up wider opportunities for recipients. They also offer prestige, enabling the scientists to seek funding more easily or form new collaborations.

7.Who are EFMC?
– EFMC is an independent association representing medicinal chemistry societies from Europe and Israel. They aim at promoting the advancement of research in this field.

8.What is Medicinal Chemistry?
– Medicinal Chemistry can be defined as a branch within chemistry focused on discovery, development, identification and interpretation of new therapeutic agents or drugs.

9.Why is it important to develop new active substances for infections?
– The development of new active substances against infections is crucial due to the rise in drug-resistant microbial strains. It’s necessary to ensure effective treatments for bacterial and viral infections continue being available.

10.How does medicinal chemistry contribute towards improving health conditions?
– Medicinal chemistry contributes towards improving health by helping discover and create novel drugs or treatments that can deal with various diseases effectively.

Originamitteilung:

Martin Empting works towards the development of new active substances that can be used to treat bacterial and viral infections. He has now been awarded the Young Medicinal Chemist in Academia Prize by the European Federation of Medicinal Chemistry (EFMC) as a runner-up. This prize is aimed at young chemists who are pursuing a career in academic research.

share this recipe:
Facebook
Twitter
Pinterest

Weitere spannende Artikel

Gutes Komplikationsmanagement nach Operationen – Warum die Failure-to-Rescue-Rate im Qualitätsbericht stehen sollte

Patientinnen und Patienten sollten bei der Wahl ihres Krankenhauses nicht nur auf die Erfahrung des Operateurs achten. Denn gerade bei komplexen und risikoreichen Eingriffen kommt es neben dem erfolgreichen Eingriff auch auf das Beherrschen der Komplikationen an, die danach auftreten können. Diese Zahl gibt die sogenannte Failure to Rescue (FTR= Rettungsversagen) – Rate wieder: Sie besagt, dass eine lebensbedrohliche Komplikation nicht rechtzeitig erkannt oder nicht adäquat behandelt wurde und im schlechtesten Fall zum Tod geführt hat.

Read More

Das Gehirn bewegt sich, wenn wir es tun. DFG fördert Kooperation zu Ortszellen und räumlichem Lernen

Forschende aus Magdeburg und Erlangen untersuchen gemeinsam, wie unser Gehirn lernt, sich in Räumen zu orientieren und Erinnerungen speichert. Am Leibniz-Institut für Neurobiologie (LIN) analysieren Wissenschaftler:innen, wie Neuronen im Hippocampus unser räumliches Lernen steuern. Dafür nehmen sie im Zeitraffer auf, was im Gehirn von Mäusen geschieht, während sie verschiedene Orientierungsaufgaben lösen. So gewinnen sie umfangreiche Daten, die im zweiten Schritt von Kooperationspartnern an der Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU) mit einem eigens entwickelten KI-Tool ausgewertet werden.

Read More